Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun;26(3):125-9.
doi: 10.1097/GCO.0000000000000060.

Use of fertility drugs and risk of ovarian cancer

Brenda Diergaarde  1 , Michelle L Kurta
Affiliations
Review

Use of fertility drugs and risk of ovarian cancer

Brenda Diergaarde et al. Curr Opin Obstet Gynecol. 2014 Jun.

Abstract

Purpose of review: The purpose of this review is to highlight recent research and insights into the relationship between fertility drug use and ovarian cancer risk.

Recent findings: Results from two large case-control studies provided further evidence that fertility drug use does not significantly contribute to risk of ovarian cancer among the majority of women when adjusting for known confounding factors. However, questions regarding the effect on certain subgroups, including long-term fertility drug users, women who remain nulligravid after fertility treatment, women with BRCA1 or BRCA2 mutations and borderline ovarian tumours, still remain. In addition, it may currently just be too early to determine whether there is an association between fertility drug use and ovarian cancer risk given that many of the exposed women are only now beginning to reach the ovarian cancer age range.

Summary: Whether use of fertility drugs increases the risk of ovarian cancer is an important question that requires further investigation, in particular given the large number of women utilizing fertility treatments. Fortunately, results from recent studies have been mainly reassuring. Large well designed studies with sufficient follow-up time are needed to further evaluate the effects of fertility treatments within subgroups defined by patient and tumour characteristics.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

The authors have no conflicts of interest to report.

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. - PubMed
    1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2010. National Cancer Institute; Bethesda, MD: http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013.
    1. Wysowski DK. Use of fertility drugs in the United States, 1973 through 1991. Fertil Steril. 1993;60(6):1096–8. - PubMed
    1. Titus-Ernstoff L, Perez K, Cramer DW, et al. Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer. 2001;84(5):714–21. - PMC - PubMed
    1. Vachon CM, Mink PJ, Janney CA, et al. Association of parity and ovarian cancer risk by family history of breast or ovarian cancer in a population-based study of postmenopausal women. Epidemiology. 2002;13(1):66–71. - PubMed

Publication types

MeSH terms